A new article titled “Targeted response testing that incorporates rapid genomic analysis, for customization of treatment for a cancer patient” was featured in the Israel news outlet, The Marker.
The environment in which a cancerous tumor develops affects the ability of drugs to help eradicate it. Curesponse has developed a method for prioritizing possible treatments, including fast and targeted genomic sequencing and testing the tumor’s response to various treatments. The company hopes to launch soon in Israel.